Brief Introduction to Axicabtagene Ciloleucel (Yescarta)

Brief Introduction to Axicabtagene Ciloleucel (Yescarta)

Axicabtagene ciloleucel (trade name: Yescarta) is a chimeric antigen receptor (CAR) T-cell therapy used to treat certain types of non-Hodgkin’s lymphoma. Its mechanism of action involves extracting a patient’s own T-cells, genetically modifying them to express a CAR that can recognize and attack cancer cells, and then infusing the modified CAR-T cells back into the patient.

Axicabtagene ciloleucel is indicated for the treatment of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), particularly relapsed or refractory follicular non-Hodgkin’s lymphoma. In clinical trials, axicabtagene ciloleucel has demonstrated remarkable efficacy and a favorable safety profile, significantly improving patients’ quality of life.

Axicabtagene ciloleucel (Yescarta): An Overview

Axicabtagene ciloleucel (Yescarta) is an innovative immunocellular therapy used to treat large B-cell lymphoma, relapsed or refractory follicular lymphoma. It is a personalized treatment approach that can significantly improve patient survival and quality of life.

1. Mechanism of Action of Axicabtagene ciloleucel (Yescarta)

Axicabtagene ciloleucel (Yescarta) works by collecting a patient’s own T-cells and genetically modifying them to express a chimeric antigen receptor (CAR) that can recognize and target tumor cells. These CAR-T cells are then infused back into the patient, where they actively seek out and kill cancer cells, thereby achieving a therapeutic effect.

2. Efficacy of Axicabtagene ciloleucel (Yescarta)

Axicabtagene ciloleucel (Yescarta) has been proven effective in treating large B-cell lymphoma and relapsed or refractory follicular lymphoma. Clinical trial results have shown that many patients experienced tumor shrinkage or complete remission after receiving axicabtagene ciloleucel (Yescarta) treatment. This innovative CAR-T cell therapy provides a new hope for patients, particularly those who have not responded to conventional treatments or have relapsed.

3. Side Effects of Axicabtagene ciloleucel (Yescarta)

While axicabtagene ciloleucel (Yescarta) has demonstrated significant therapeutic efficacy, it may also cause certain side effects. Common side effects include fever, low blood pressure, chills, shortness of breath, and nausea. Additionally, this therapy may lead to severe neurological complications, such as cerebral edema and encephalitis. Therefore, before initiating axicabtagene ciloleucel (Yescarta) treatment, physicians will conduct a comprehensive evaluation of the patient and closely monitor their reactions and side effects.

Axicabtagene ciloleucel (Yescarta), as a personalized immunocellular therapy, provides an innovative treatment option for patients with large B-cell lymphoma and relapsed or refractory follicular lymphoma. It utilizes genetically modified CAR-T cells to attack cancer cells, demonstrating remarkable therapeutic effects. Patients receiving axicabtagene ciloleucel (Yescarta) treatment require close monitoring for side effects and must follow their physician’s guidance throughout the treatment process. Axicabtagene ciloleucel (Yescarta) offers a new hope for patients and opens new doors in the treatment of these types of lymphomas.